A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression

Peri, Marta; Grassadonia, Antonino; Iezzi, Laura; Vici, Patrizia; Tursi, Michele De; Natoli, Clara; Tinari, Nicola; Zilli, Marinella

doi:10.1155/2019/1018492

Cited by 4 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hematogenous distant metastasis such as lung, liver, and bone, usually occur late in the disease course. In rare instances, cutaneous metastases can be seen in vulvar carcinoma, with short survival being a predominant feature [15]. In this case admission happened at an advance stage with already involved inguinofemoral lymph nodes and pelvic bone due to poor follow-up.…”

Section: Key Clinical Pointsmentioning

confidence: 83%

“…Therapeutic management for vulvar SCC with metastasis is preferred to be chemotherapeutic palliative regiment and usually are the same regimen which chosen for advanced cervical or anal cancers [19]. To date, there is no specific chemotherapeutic regimen for both type of vulvar SCC, HPV-related or HPV-independent tumors [15].…”

Section: Managementmentioning

confidence: 99%

“…Vulvar SCC can progress rapidly, become refractory to chemotherapy and can unexpectedly show dismal prognosis even if diagnosed at an early stage [15]. There is an urgent need for novel treatment, work-up, screening and diagnostic guideline.…”

Section: Areas Of Uncertaintymentioning

confidence: 99%

See 2 more Smart Citations

Vulvar Squamous Cell Carcinoma in a Patient with AIDS: A Case Study

Ayat¹,

Sharif²,

Hewitt³

et al. 2020

AJMCR

View full text Add to dashboard Cite

Vulvar cancer comprises 5% of gynecological cancers with squamous cell carcinoma (SCC) being found in 90% of the cases. Vulvar intraepithelial neoplasia is human papilloma virus (HPV)-driven and is the precursor lesion in nearly 40% of all cases of vulvar SCC. Pruritus is reported as the most common initial manifestation of vulvar SCC which may be of a long duration with pain, discharge, and bleeding been less frequently reported which contributes to the delayed initial presentation of the disease. So far, there are no recommended screening strategies for vulvar cancer and HPV vaccination may be the only effective way for prevention. We present a case of advanced vulvar cancer in an immunocompromised host. We will review pertinent topics for the clinicians on HPV infection prevention, clinical course, staging and the need for strong efforts on patient education.

show abstract

Section: Key Clinical Pointsmentioning

confidence: 83%

Section: Managementmentioning

confidence: 99%

See 1 more Smart Citation

Vulvar Squamous Cell Carcinoma in a Patient with AIDS: A Case Study

Ayat¹,

Sharif²,

Hewitt³

et al. 2020

AJMCR

View full text Add to dashboard Cite

show abstract

“…Vulvar cancer mainly occurs in older women, primarily those who are postmenopausal. 17 The peak age of incidence of vulvar cancer has been reported as >70 years; however, the peak period for vulvar cancer among Chinese women is <60…”

Section: Discussionmentioning

confidence: 99%

<p>Success of <sup>125</sup>I-Seed Treatment in Vulvar Squamous-Cell Carcinoma with Aplastic Anemia: A Case Report</p>

Ni¹,

Chi²,

Guo³

et al. 2020

OTT

View full text Add to dashboard Cite

“…In vulvar carcinoma, the most common is lymphatic dissemination, the inguinal lymph nodes being the first station of spread. The hematogenous pathway of distant dissemination occurs in the late stages [3].…”

Section: Introductionmentioning

confidence: 99%

What to do when nothing else is left to be done - metastatic non-HPV vulvar squamous cell carcinoma with multiple lines of chemotherapy

Stana¹,

Deac²,

Căinap³

2021

Arch Clin Cases

View full text Add to dashboard Cite

Recurrent vulvar squamous cell carcinoma with multiple site metastases is a rare entity – (up to 14.2% of the total number of recurrences), with a poor prognosis (only 15% of the patients alive at 5 years). Due to its “hard to find” character, there are no standardized guidelines available and the treatment is extrapolated from advanced cervical carcinoma, anal carcinoma and other squamous cell carcinomas. Immunotherapy has shown some positive results in vulvar carcinoma with PD-L1 positive, high TMB, high MSI or with MMR deficiency. An alternative for selected cases without therapeutic resources could be the HPV vaccine. We present the case of a 64-year-old woman diagnosed in 2014 with vulvar squamous cell carcinoma stage II for which she underwent radical vulvectomy with bilateral inguinal lymphadenectomy followed by external radiotherapy. In 2019 she developed local recurrence associated with lung, pleural, lymph nodes and subcutaneous metastasis, treated with three lines of chemotherapy: paclitaxel/carboplatin followed by cisplatin/5-fluorouracil and carboplatin/gemcitabine. The patient’s general health status altered progressively, and she died after the 4th cycle of carboplatin/gemcitabine. This case’s management could be a starting point for the vulvar carcinoma cases where the standard therapeutical options do not represent a choice anymore, providing the necessary example on how to approach it.

show abstract

A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression

Cited by 4 publications

References 12 publications

Vulvar Squamous Cell Carcinoma in a Patient with AIDS: A Case Study

Vulvar Squamous Cell Carcinoma in a Patient with AIDS: A Case Study

<p>Success of <sup>125</sup>I-Seed Treatment in Vulvar Squamous-Cell Carcinoma with Aplastic Anemia: A Case Report</p>

What to do when nothing else is left to be done - metastatic non-HPV vulvar squamous cell carcinoma with multiple lines of chemotherapy

Contact Info

Product

Resources

About